Clovis Oncology Announces Third Quarter 2021 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Clovis Oncology (CLVS) Misses Q3 EPS by 8c; Reports $171.9M in Cash and Cash Equivalents
November 3, 2021 8:11 AM EDTClovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.9 million versus the consensus estimate of $39.09 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More